Back to top
more

Integra LifeSciences (IART)

(Delayed Data from NSDQ)

$26.70 USD

26.70
1,733,125

+1.79 (7.19%)

Updated Nov 6, 2024 04:00 PM ET

After-Market: $26.69 -0.01 (-0.04%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value F Growth F Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 35% (89 out of 251)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

STERIS (STE) to Report Q1 Earnings: What's in the Cards?

by Zacks Equity Research

STERIS (STE) registers declines in Healthcare Products with neutral performance in Life Science and AST in April, which is likely to have impacted Q1 earnings.

T2 Biosystems (TTOO) to Post Q2 Earnings: What's in Store?

by Zacks Equity Research

T2 Biosystems' (TTOO) second-quarter results are likely to reflect growth in product revenues.

Zimmer Biomet (ZBH) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Zimmer Biomet's (ZBH) Hips and Knees portfolios are expected to have contributed to second-quarter top line despite pandemic-led business disruptions.

Henry Schein (HSIC) to Report Q2 Earnings: What's in Store?

by Zacks Equity Research

Henry Schein's (HSIC) medical business' PPE sales are likely to have boosted Q2 performance amid the coronavirus pandemic.

Invitae (NVTA) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Genetic testing is likely to drive Invitae's (NVTA) Q2 earnings.

Will Delayed Orders Hurt Ekso Bionics (EKSO) Q2 Earnings?

by Zacks Equity Research

Ekso Bionics (EKSO) Q2 earnings are expected to have been boosted by its recent efforts to grow virtual connectivity with customers and to reduce costs.

Zynex (ZYXI) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Zynex's (ZYXI) April orders down approximately 35% from the January and February average. This may have impacted its Q2 earnings.

Aphria (APHA) to Report Q4 Earnings: What's in the Offing?

by Zacks Equity Research

Aphria's (APHA) fiscal fourth-quarter results are likely to reflect higher sales from medical and adult-use cannabis products.

Stryker (SYK) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Stryker's (SYK) second-quarter results are likely to reflect weak segmental performances at Medsurg, Orthopaedic and Neurotechnology & Spine.

Baxter (BAX) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Baxter's (BAX) second-quarter performance is likely to reflect growth in its five global business units.

What's in Store for IDEXX Laboratories (IDXX) in Q2 Earnings?

by Zacks Equity Research

IDEXX's (IDXX) top line is likely to have benefited from a robust CAG business and regulatory approvals for its COVID-19 tests.

Bio-Rad (BIO) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in product demand related to COVID-19 testing and research is likely to have aided Bio-Rad's (BIO) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

DaVita (DVA) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Solid performance within net dialysis and related lab patient service segment is likely to have contributed to DaVita's (DVA) top line in Q2.

Cerner (CERN) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Cerner's (CERN) second-quarter results are likely to reflect solid show by Subscriptions, Managed Services and Licensed software segments.

DexCom (DXCM) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

DexCom's (DXCM) second-quarter results are likely to reflect rising global awareness of its real-time CGM.

Quidel (QDEL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Quidel (QDEL) is likely to have witnessed an uptick in rapid immunoassay revenues in Q2.

Deferred Procedures to Mar Boston Scientific (BSX) Q2 Earnings

by Zacks Equity Research

With lockdowns continuing through all three months of the second quarter, Boston Scientific (BSX) is expected to have faced a more dreadful time.

PerkinElmer (PKI) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

PerkinElmer's (PKI) second-quarter results are likely to reflect strong performance at Diagnostics segment. However, forex remained a woe.

ViewRay (VRAY) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Strength in MRIdian system business is likely to have aided ViewRay's (VRAY) performance in second-quarter 2020 amid the coronavirus-led economic doldrums.

Ecolab (ECL) to Report Q2 Earnings: What's in the Offing?

by Zacks Equity Research

Ecolab's (ECL) Global Industrial segment is likely to have gained from the Water, Food & Beverage and Life Sciences sub-units in Q2.

Can Diagnostics Aid Hologic (HOLX) Q3 Earnings Amid Coronavirus?

by Zacks Equity Research

Strength in segmental business is likely to have aided Hologic's (HOLX) performance in third-quarter fiscal 2020 amid the coronavirus-led economic doldrums.

Growing Testing Capacity to Aid LabCorp's (LH) Q2 Earnings?

by Zacks Equity Research

LabCorp's (LH) developments to support COVID-19 testing are believed to have contributed to the company's second-quarter earnings.

Testing Volume to Aid Quest Diagnostics' (DGX) Q2 Earnings?

by Zacks Equity Research

Looking at this demand for testing, Quest Diagnostics (DGX) has significantly picked up capacity to perform molecular diagnostic tests a day.

What's in Store for West Pharmaceutical's (WST) Q2 Earnings?

by Zacks Equity Research

West Pharmaceutical Services (WST) is likely to have gained from continued strength in high-value product sales in Q2.

What's in the Cards for Intuitive Surgical (ISRG) Q2 Earnings?

by Zacks Equity Research

Intuitive Surgical's (ISRG) second-quarter earnings are likely to reflect weaker-than-expected performance at Instruments & Accessories segment and decline in da Vince procedure volume.